Full A Call for Consensus in Defining Efficacy in Clinical Trials for Opioid Addiction: Combined Results from a Systematic Review and Qualitative Study in Patients Receiving Pharmacological Assisted Therapy for Opioid Use Disorder

CURRENT STATUS: ACCEPTED

Brittany B. Dennis
McMaster University

Nitika Sanger
McMaster University

Monica Bawor
St. George's University of London

Leen Naji
McMaster University

Andrew Worster
McMaster University

Natasha Baptist-Mohseni
McMaster University

Alannah Hillmer
McMaster University

Danielle Rice
Ottawa health research institute

Kim Corace
Royal Ottawa Mental Health Centre

Brian Hutton
Ottawa Health Research Institute

Peter Tugwell
Abstract

Background

Given the complex nature of opioid addiction treatment and the rising number of available opioid substitution and antagonist therapies (OSAT), there is no ‘gold standard’ measure of treatment effectiveness, and each successive trial measures a different set of outcomes which reflect success in arbitrary or opportune terms. We sought to describe the variation in current outcomes employed across clinical trials for opioid addiction, as well as determine whether a discrepancy exists between the treatment targets that patients consider important and how treatment effectiveness is measured in the literature.

Methods

We searched nine commonly used databases (e.g. EMBASE, MEDLINE) from inception to August 1, 2015. Outcomes used across trials were extracted and categorized according to previously established domains. To evaluate patient reported goals of treatment, semi-structured interviews were conducted with 18 adults undergoing methadone treatment.

Results

We identified 60 trials eligible for inclusion. Once outcomes were categorized into eight broad domains (e.g. abstinence/substance abuse), we identified 21 specific outcomes with furthermore 53 subdomains and 118 measurements. Continued opioid use and treatment retention were the most commonly reported measures (46%, n=28). The majority of patients agreed that abstinence from opioids was a primary goal in their treatment, however they also stressed goals under-reported in clinical trials.

Conclusion

There is inconsistency in the measures used to evaluate the effectiveness of OSATs. Individual and population level decision making is being guided by a standard of effect considered useful to researchers yet in direct conflict with what patients deem important.

PROSPERO ID

CRD42013006507
Background
Information retrieved from the highest quality evidence—most often from randomized controlled trials (RCTs)—is used to inform health care decisions at individual and population levels. From the development of research questions to decisions regarding “significant” treatment targets, researchers control evidence generation in its entirety. We rely on their expert opinion to design studies and trust they select the appropriate outcomes reflecting treatment success. Despite best interests, the value of many pharmacological interventions is commonly evaluated on their observed effect across different biochemical and surrogate measurements.\(^1\) Frequently these measurements neither reflect nor acknowledge the values and preferences of the populations they are meant to serve. Patient important outcomes reflect the health concerns, fears regarding adverse drug reactions, treatment goals, and overall values of patient populations. These outcomes are often underrepresented in comparison to biologic measurements closely associated with the physiologic disease process.\(^1\) For instance, the majority of trials within the diabetes literature include primary endpoints such as blood glucose level as an indicator of efficacy due to its direct relation to the pathophysiology of diabetes. Outcomes such as death, stroke, infection, pain function, or delayed wound healing have significant impact on patients’ lives, yet are often underreported.\(^2\) Unfortunately, patient important outcomes are often neglected in trials aimed to establish treatment benefit; this deficit is of substantial concern to the growing evidence base in opioid addiction; known formally as opioid use disorder (OUD).\(^3\)

Given the complex nature of OUD treatment and the rising number of available pharmacological opioid substitution and antagonist therapies (OSAT), there is no ‘gold standard’ measure of treatment effect and each successive trial measures a different set of treatment outcomes which reflect success in arbitrary or opportune terms.\(^4-6\) Commonly included endpoints comprise attrition rates, illicit substance use, presence of medical and psychiatric comorbidity, social function as measured by current housing arrangements, collective neighborhood income, educational achievement, employment, and involvement in criminal activity.\(^4,7,8\) The variation in the selection of outcomes as well as the marked range of definitions, instruments, and measurements of specific outcomes
demand the need for further research to establish a summary of the current outcomes utilized in the literature, as well as determine which outcomes reflect patient’s values and preferences for the end goals of addiction treatment.

In the current study, we sought to outline the current outcomes employed in clinical trials for opioid addiction, as well as to determine whether a divide exists between the treatment targets patients consider important and those selected to evaluate efficacy in the literature.

Methods
This study was completed using a mixed-methods design in two phases. In the first phase of the study we completed a systematic review which aimed to describe outcomes used in the current literature to establish effectiveness of different OSATs. The second phase aimed to determine patient’s perspectives of successful addiction treatment with emphasis on the patient’s end-goals of therapy.

Phase 1 of this study used the previously published protocol for a systematic review and network meta-analysis comparing OSAT interventions for OUD during which we also extracted the listing of outcomes reported within each study. The literature search was completed in August 2015; this was not updated for the current study given that the emphasis is not on establishing a superior therapy for addiction, but rather to provide a summary of the outcome measures employed across clinical trials comprising the main body of evidence.

Phase 1: Systematic Review to Establish Outcomes Used in the Current Literature

Methodology
We performed a systematic review to identify all OSAT trials. A greater detail of our study methods can be found in the published protocol. This study was registered in the PROSPERO database (CRD42013006507) and adheres to the PRISMA guidelines.

Studies were limited to trials evaluating pharmacological therapies for opioid addiction in general addiction populations, any studies in special populations including prison were excluded. No studies were eliminated based on outcome selection. We also contacted all primary investigators listed on the NIH Clinical Trial Registry from eligible studies identified during the title screening to inform them of this review and inquire for information regarding any publications resulting from their trials. This
review placed no constraints on language or date of publication. Animal studies and incomplete studies (pilot, preliminary reports) were excluded. Studies without comparison groups were also excluded (i.e. case-report or case-series). Methodological quality assessment was conducted using the Cochrane Risk of Bias Tool for RCTs.

Summary of Outcomes Used Across OSAT Trials

The primary aim of the current study was to summarize all outcome domains, subdomains and their definitions and outcomes measurements/instruments used for each outcome in trials of OSAT for OUD. Data extraction forms were constructed and pilot tested for use in this review. We abstracted the sample size, mean age, eligibility criteria, intervention description, dose, approaches to missing data, outcome definition, outcome measurement, covariates included in regression models if adjusted analyses were performed, and the statistical association reported (e.g. Odds Ratio[OR], Relative Risk [RR]).

To provide an organized summary, we structured outcomes into broader categories according to the domains proposed by commonly used measurement scales evaluating addiction severity (i.e., the Addiction Severity Index [ASI]\textsuperscript{12} and Maudsley Addiction Profile [MAP]).\textsuperscript{13} These tools evaluate treatment response using the broader domains of substance use behavior, physical and mental health, and social functioning.\textsuperscript{12,13} Both tools are practical and provide a global assessment of patients’ physical and social functioning. Our outcome domains included physical health, psychiatric health and symptoms, abstinence and substance use behavior, and personal and social functioning.

Some studies used additional outcomes that did not conform to these domains; thus, we included global quality of life and addiction severity assessments (including global addiction severity, intervention adherence, acceptance of intervention, and resource utilization (e.g. hospital admission) as additional domains. This categorization of outcome domains and subdomains provides researchers and clinicians with an overview of the current outcomes used to assess patients’ response to OSAT.

All outcomes used across trials included in this review were extracted and categorized according to the above described criteria.
Phase 2: Qualitative Interviewing of Patients on Pharmacological Treatment for OUD

Recruitment and Interview Methodology

Patients were recruited from two opioid addiction treatment centers in Ontario, Canada using purposive sampling. The research collaborative between the Population Genomics Program at McMaster University and the Canadian Addiction Treatment Centers (CATC) provided a framework for study recruitment, data collection, data analysis, and follow-up. Eligibility criteria included: patients ≥18 years, currently receiving an opioid substitution therapy including methadone maintenance treatment or buprenorphine, able to understand and speak English and able to provide informed consent. The Hamilton Integrated Research Ethics Board (HiREB) approved this study (HiREB Study ID 0168). This study adheres to the STROBE guidelines.

Qualitative methods were used to establish patients’ perspectives of successful addiction treatment. Structured open-ended interviews were conducted to explore each patient’s end-goals of therapy. These interviews identified common themes with regard to addiction treatment goals. The interviews were transcribed and analyzed for themes, clarifications, and deeper understanding of the topics outlined above.

Convenience sampling was utilized between two addiction treatment clinics. Recruiting from two separate sites allowed for a broader patient demographic to be covered, as socioeconomic status and homelessness rates were known to differ between sites. Flyers advertising the study were posted at both clinical sites. All patients eligible for recruitment were also approached and informed about the study objectives by the clinic’s healthcare staff. Upon gaining informed consent, patients were given a demographic questionnaire and interviewed by two investigators using structured questions and open-ended questions. No one else was present at these interviews. All patients included in the study were given a five-dollar gift card at the end of the interview.

Interviews were conducted by an addiction specialist nurse Carolyn Platter (BScNurs), and two female research coordinators, Julia Woo (BHSc) and Anuja Bhalerao (BHSc). These team members have
performed hundreds of interviews in this population since working with the McMaster GENOA research collaborative. The interviewers were selected in efforts to minimize potential bias generated during data collection. These team members had no previous stake in the research question or design of this study. All interviewers underwent ethics and sensitivity training prior to meeting the patients, as per McMaster University Research Ethics Board Guidelines. Each team member has completed the Tri-Council Policy Statement course. The patients recruited into the study had not been previously interviewed by the team members and we are confident there was no relationship between participants are interviewers prior to the interview. Participants were briefed as to the goals of the study, particularly our aim of establishing whether current research accurately reflects what they wish to gain from treatment.

Interviews were completed using a structured piloted questioning tool with prompts, patients were approached allowing for open ended answers. Each interview was audio recorded for later transcription. Each interviewer also made field notes, which were used to aid in later transcription. Each interview transcript was carefully investigated for insight into the major research question, “How would you measure success in methadone maintenance or buprenorphine treatment?” We also provided patients a list of commonly anticipated treatment goals and asked them to rank which aspect of recovery meant the most to their addiction treatment. Patients were allowed to rank up to four items. The list provided a summary of different potential goals across substance abuse, physical health, emotional stability, and personal functioning domains. A register of these goals can be found in the Supplementary Web Appendix. The interviews lasted approximately 40 minutes and were conducted on site at the treatment facility between the dates of September 2015 and February 2016. Interviews were conducted until responses to the major research questions were saturated, having no new themes emerge.¹⁶ Patients were not provided transcribed copies of interview.

Analysis

Interviews were transcribed and evaluated for the common definitions of success in addiction treatment as well as aspects of recovery patients found important. Two primary interviewers (AB, JW) were responsible for coding the data, unaided software. This process was later reviewed by all
members of the team. These responses were coded according to the broader domains proposed by popular measurement scales evaluating addiction severity; the ASI\textsuperscript{12} and MAP.\textsuperscript{13} Additional domains not included in the MAP or ASI were also added. These domains included global quality of life and addiction severity assessments (including global addiction severity measure scores), intervention adherence, acceptance of intervention, and resource utilization (e.g., hospital admission).\textsuperscript{16}

Due to small size and limited power of our sample, no statistical tests were conducted in reference to significant differences between the participants at the two sites.\textsuperscript{16}

Results

Phase I: Findings from the Systematic Review

An annotated flow diagram of the study selection process is presented in Figure 1. We searched databases since inception to August 1, 2015 and identified 6,077 articles. We identified 60 trials with a combined participant sample of 13341 patients eligible for full text-extraction.\textsuperscript{19-78} A summary of the included trials is available in the Supplementary Web Appendix. Table 1 summarizes the outcome domains and sub-domains used across trials included in this study; the outcomes are categorized into broad domains, outcome domains, subdomains and the specific measurements. Within the 8 broadest domains (abstinence and substance use behavior, physical health, psychiatric health and symptoms, personal and social functioning, resource utilization, intervention adherence, intervention acceptance, and global quality of life and addiction severity), there are 21 more specific outcome domains (e.g., illicit opioid use, illicit non-opioid substance use), and across these outcomes there exists 53 separate definitions or measurements.

Of the 60 trials eligible for inclusion to this review, retention in treatment was the most commonly measured and reported outcome. Of the 28 studies reporting retention in treatment as their primary outcome, 16 different interventions were evaluated. The second most commonly reported outcome was illicit opioid use, which took 17 definitions and a further eight variations in measurement.

Phase II: Qualitative Interviewing of Patients on Pharmacological Treatment for Opioid Addiction
A total of 18 individuals from two treatment centers participated in this study. Sixteen of the participants were currently undergoing MMT at the time of recruitment and 2 participants were receiving buprenorphine but had received MMT at least one year prior. The mean age of the participants was 36.11 (SD=10.01) years with majority female (67%) and of Caucasian ethnicity (89%). Participants in one site had a higher mean income ($48,750 vs $35,000) and were more likely to be employed (63% vs 40%) when compared to the second site’s participants which is expected and selected purposefully to be economically different. All participants were interviewed in a single session, no repeated sessions were necessitated during the course of this study.

**Qualitative Interview**

The majority of participants (61.1%) identified their main goal of methadone treatment as being abstinent from drugs. This goal was clearly indicated by patients, including statements like: “Just being completely off of drugs. To never touch drugs again”. Close to a third of these individuals had a more specific goal of being off of methadone completely (38%). One participant stated specifically (as seen in the following direct quote) that even though they are sober, their ultimate goal is to be “clean” from all opioids.

“When someone tells me I’m not sober because I’m on methadone. I tell them I may not be clean because I’m putting this medication in my body but I am sober. I want to be clean. To me, I’m sober right now, I have been sober for two and a half years. I haven’t touched the drugs for two and a half years. At the end of it, I want to be off the methadone completely but I want to be able to taper down till I no longer need it anymore and I want to look back and say that was just a phase in my life. I took the necessary steps to make myself better and I accomplished that. And all the things that I accomplished being on methadone too. So yeah, I just want to get off of it completely, eventually”

Others did not desire to be off methadone and specified methadone was helping them. One participant’s main goal was for pain control and not to be off methadone, as it helped them function and be able to move. When asked if they were hoping to get completely off methadone they responded saying, “I don’t know if I ever will. I see my doses being reduced but until my health problems are resolved, I have absolutely no problem being on it if it has to be for the rest of my life.”
Other goals of methadone treatment that were not as common included being able to get back to their usual lives and able to maintain it, to not be sick and to manage addictions not only related to drugs but addictions in other domains of their life. Participant’s verbatim responses are summarized in Table 2.

Response to predetermined treatment goals

Seventeen out of the 18 participants completed section indicating which aspect of recovery meant the most to their addiction treatment. Please refer to Figure 2 for a graphical summary of patients’ first ranked treatment goals.

Abstinence from opioid use was the most commonly selected outcome overall followed by stability of relationships, reduced money spent on drugs, reduced drug craving, employment, regaining physical health, pain control, coping, reduced depression, stable housing, improved sexual function, decreased risk of overdose, reduced injecting and reduced anxiety overall across all participants’ four outcome choices. The most commonly selected primary outcome for participants was abstinence from opioid use, with 47% (8) of participants selecting it as their first choice. 16.6% (3) chose money spent on drugs as their second most important outcome. Participant’s outcomes are summarized in Table 3.

Discussion

Findings from this study outline the current outcomes employed in clinical trials for opioid addiction, and also provide a unique insight into the treatment goals patients consider important when receiving pharmacological therapies for OUD.

Results from this systematic review highlight a major lack of consensus in our evidence base when determining appropriate end-points for establishing treatment effectiveness in OUD. A substantial number of outcomes as well as variations in the definitions and measurements of the same outcomes were reported across trials. Despite the overwhelming collection of outcomes employed by trialists, substance use—specifically opioid—and treatment retention remain the most consistently reported. Trialists seldom explored pharmacological effect on personal and social functioning outcomes such as criminal behavior, employment, relationships, and personal stability end-points including type of accommodation (20%, n=12).
The most commonly employed outcomes used to establish effectiveness were in stark contrast to the goals for treatment patients described in the qualitative interviews performed for the second phase of our study. While the majority of patients agreed that abstinence and reduction in opioid use was a primary goal in their treatment, they also stressed goals for therapy comprising employment, improved relationship stability, reduction in the money spent on drugs, as well as the improvement in physical and psychiatric symptoms such as pain, depression, and anxiety. Regrettably, these outcomes were rarely reported or of primary focus in the clinical trials.

When assessing the comparative effectiveness of all interventions among patients receiving OSATs, retention in treatment was the most consistently measured and reported outcome across trials (46%, n=28). In direct contrast to staying on treatment, our interviews with patients demonstrate an eagerness to complete therapy and get off the methadone treatment regime as a recurrent theme. Outcome selection bears serious implications for the interpretation of the results as well as our ability to extrapolate such findings in a wider clinical context. These methodological shortcomings highlight the need for new assessment strategies for opioid addiction treatment options, where future efforts should consider targeting the objective assessment of treatment effectiveness employing long-term follow-up using administrative data-linkage for trial participants to evaluate hard long-term outcomes such as incidence of hepatitis, HIV, cardiovascular abnormalities, and mortality. Among the trials included in this review, three evaluated the impact of interventions on mortality\textsuperscript{47,79} or cardiac function.\textsuperscript{50}

Trials evaluating OSATs suffer from poor methodological quality. A combination of small sample size, poor design, highly stringent eligibility criteria, effect estimates with tremendous imprecision, short- follow up time, missing data, and a major lack of consensus over patient-important outcomes has led to an accumulation of a large yet very weak body of evidence. Whether it be illicit opioid use or risky behavior, the large number of definitions and measurements used to assess the same attribute suggest the need for more consensus in the field and understanding of what treatment outcomes are most important to addiction patients.

Conclusions
In agreement with current guidelines, our study demonstrates there is limited consistency in the evidence used to evaluate the effectiveness of OSATs. More concerning, our treatment recommendations and clinical decisions are being guided by a standard of effect considered useful to researchers yet in direct conflict with what patients deem important. This is a substantial limitation in the literature. Without the identification of a measurable treatment outcome that has an impact and significance to patients, services, and the population as a whole, all the investment in trials will result in inadequate and inconsistent “efficacy” with limited, if any, external validity. We demonstrate here the need for an established set of OSAT outcomes guided by all stakeholders to inform clinicians of the true efficacy of these therapies and guide trialists to ensure our future understanding of these treatments accurately reflects the priorities of our patient population.

References

1. Deshpande, P. R., Rajan, S., Sudeepthi, B. L. & Abdul Nazir, C. P. Patient-reported outcomes: A new era in clinical research. *Perspect. Clin. Res.* **2**, 137-44 (2011).

2. Montori, V. M., Wang, Y. G., Alonso-Coello, P. & Bhagra, S. Systematic evaluation of the quality of randomized controlled trials in diabetes. *Diabetes Care* **29**, 1833-1838 (2006).

3. *Diagnostic and statistical manual of mental disorders (5th ed.)*. (American Psychiatric Publishing, 2013).

4. Mattick Richard, P., Breen, C., Kimber, J. & Davoli, M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database of Systematic Reviews* (2009). doi:10.1002/14651858.CD002209.pub2

5. Hedrich, D. *et al.* The effectiveness of opioid maintenance treatment in prison settings: a systematic review. *Addiction* **107**, 501-517 (2012).

6. Li, Y., Kantelip, J.-P., Gerritsen-van Schieveen, P. & Davani, S. Interindividual variability of methadone response. *Mol. Diagn. Ther.* **12**, 109-124 (2008).

7. Hedrich, D. *et al.* The effectiveness of opioid maintenance treatment in prison
settings: a systematic review. *Addiction* **107**, 501-517 (2012).

8. Li, Y., Kantelip, J.-P., Gerritsen-van Schieveen, P. & Davani, S. Interindividual variability of methadone response. *Mol. Diagn. Ther.* **12**, 109-124 (2008).

9. Dennis Brittany Burns and Naji, L. and B. M. and B. A. and V. M. and D. J. and P. C. and P. G. and M. D. C. and W. A. and D. D. and S. Z. and T. L. The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol. *Syst. Rev.* **3**, 105 (2014).

10. Dennis, B. B. *et al.* The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol. *Syst Rev 3*, 105 (2014).

11. Shamseer, L. *et al.* Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: Elaboration and explanation. *BMJ (Online)* **349**, (2015).

12. McLellan, A. T. *et al.* The fifth edition of the Addiction Severity Index. *J. Subst. Abuse Treat.* **9**, 199-213 (1992).

13. Marsden, J. *et al.* The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. *Addiction* **93**, (2002).

14. Sinha, R., Fuse, T., Aubin, L.-R. & O’Malley, S. S. Psychological stress, drug-related cues and cocaine craving. *Psychopharmacology (Berl).* **152**, 140-148 (2000).

15. Morissette, A., Ouellet-Plamondon, C. & Jutras-Aswad, D. Craving as a core symptom in substance use disorders: epidemiology, neurobiological substrates and clinical relevance/Le craving comme symptome central de la toxicomanie: de ses fondements neurobiologiques a sa pertinence clinique. *Sante Ment. Que.* **39**, 21–38 (2014).

16. Woo, J. *et al.* “Dont judge a book by its cover”: A qualitative study of methadone patients’ experiences of stigma. *Subst. Abus. Res. Treat.* (2017).

doi:10.1177/1178221816685087
17. von Elm, E. et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ* **335**, 806-808 (2007).

18. Dennis, B. B. et al. Opioid substitution and antagonist therapy trials exclude the common addiction patient: A systematic review and analysis of eligibility criteria. *Trials* **16**, 1 (2015).

19. Ahmadi, J. & Ahmadi, K. Controlled trial of maintenance treatment of intravenous buprenorphine dependence. *Ir J Med Sci* **172**, 171-173 (2003).

20. van den Brink, W. et al. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. *BMJ* **327**, 310 (2003).

21. Ling, W., Wesson, D. R., Charuvastra, C. & Klett, C. J. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. *Arch Gen Psychiatry* **53**, 401-407 (1996).

22. Schottenfeld, R. S., Chawarski, M. C. & Mazlan, M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. *Lancet* **371**, 2192-2200 (2008).

23. Johnson, R. E. et al. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. *Drug Alcohol Depend* **40**, 17-25 (1995).

24. Ahmadi J Moosavinasab M, Babaee M, Firoozabadi A, Mohagheghzadeh M., et al, F. H. Treatment of heroin dependence. *Ger. J. Psychiatry* **7**, 1-5 (2004).

25. Ahmadi, J. A controlled trial of buprenorphine treatment for opium dependence: the first experience from Iran. *Drug and Alcohol Dependence* **66**, 111-114 (2002).

26. Yancovitz, S. R. et al. A randomized trial of an interim methadone maintenance clinic. *Am J Public Heal.* **81**, 1185-1191 (1991).

27. Sees, K. L. et al. Methadone maintenance vs 180-day psychosocially enriched
detoxification for treatment of opioid dependence: a randomized controlled trial. *JAMA* **283**, 1303–1310 (2000).

28. Strain, E. C., Stitzer, M. L., Liebson, I. A. & Bigelow, G. E. Comparison of buprenorphine and methadone in the treatment of opioid dependence. *Am J Psychiatry* **151**, 1025–1030 (1994).

29. Soyka, M., Zingg, C., Koller, G. & Kuefner, H. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. *Int J Neuropsychopharmacol* **11**, 641–653 (2008).

30. March, J. C., Oviedo-Joekes, E., Perea-Milla, E. & Carrasco, F. Controlled trial of prescribed heroin in the treatment of opioid addiction. *Journal of Substance Abuse Treatment* **31**, 203–211 (2006).

31. Comer, S. D. *et al.* Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. *Arch Gen Psychiatry* **63**, 210–218 (2006).

32. Eder, H. *et al.* Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy. *Addiction (Abingdon, England)* **100**, 1101–1109 (2005).

33. Eissenberg, T. *et al.* Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence. A randomized clinical trial. *JAMA* **277**, 1945–1951 (1997).

34. Jaffe, J. H. *et al.* Methadyl acetate vs methadone. A double-blind study in heroin users. *JAMA* **222**, 437–442 (1972).

35. Kamien, J. B., Branstetter, S. A. & Amass, L. Buprenorphine-naloxone versus methadone maintenance therapy: A randomised double-blind trial with opioid-dependent patients. *Heroin Addiction and Related Clinical Problems* **10**, 5–18 (2008).

36. King, V. L. *et al.* A 12-month controlled trial of methadone medical maintenance
integrated into an adaptive treatment model. *J Subst Abus. Treat* **31**, 385-393 (2006).

37. Oviedo-Joekes, E. *et al.* Diacetylmorphine versus Methadone for the Treatment of Opioid Addiction. *N. Engl. J. Med.* **361**, 777-786 (2009).

38. Oviedo-Joekes, E., March, J. C., Romero, M. & Perea-Milla, E. The Andalusian trial on heroin-assisted treatment: a 2 year follow-up. *Drug Alcohol Rev* **29**, 75-80 (2010).

39. Potter, J. S. *et al.* Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). *J Stud Alcohol Drugs* **74**, 605-613 (2013).

40. Robertson, J. R. *et al.* Addressing the efficacy of dihydrocodeine versus methadone as an alternative maintenance treatment for opiate dependence: A randomized controlled trial. *Addiction* **101**, 1752-1759 (2006).

41. Saxon, A. J. *et al.* Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. *Drug Alcohol Depend* **128**, 71-76 (2013).

42. Anglin, M. D., Conner, B. T., Annon, J. & Longshore, D. Levo-alpha-acetylmethadol (LAAM) versus methadone maintenance: 1-year treatment retention, outcomes and status. *Addiction* **102**, 1432-1442 (2007).

43. Schwartz, R. P., Kelly, S. M., O’Grady, K. E., Gandhi, D. & Jaffe, J. H. Interim methadone treatment compared to standard methadone treatment: 4-month findings. *J Subst Abus. Treat* **41**, 21-29 (2011).

44. Schwartz, R. P. *et al.* A randomized controlled trial of interim methadone maintenance. *Arch Gen Psychiatry* **63**, 102-109 (2006).

45. Strain, E. C., Stitzer, M. L., Liebson, I. A. & Bigelow, G. E. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and
addiction severity index. Journal of clinical psychopharmacology 16, 58–67 (1996).

46. Wolstein, J. et al. A randomized, open-label trial comparing methadone and Levo-Alpha-Acetylmethadol (LAAM) in maintenance treatment of opioid addiction. Pharmacopsychiatry 42, 1–8 (2009).

47. Ling, W., Charuvastra, V. C., Kaim, S. C. & Klett, C. J. Methadyl acetate and methadone as maintenance treatments for heroin addicts: a Veterans Administration cooperative study. Arch. Gen. Psychiatry 33, 709–720 (1976).

48. White, J. M. et al. Relationship between LAAM-methadone preference and treatment outcomes. Drug Alcohol Depend 66, 295–301 (2002).

49. Kosten, T. R., Schottenfeld, R., Ziedonis, D. & Falcioni, J. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis 181, 358–364 (1993).

50. Wedam, E. F., Bigelow, G. E., Johnson, R. E., Nuzzo, P. A. & Haigney, M. C. P. QT-interval effects of methadone, levo-methadyl, and buprenorphine in a randomized trial. Arch. Intern. Med. 167, 2469–2475 (2007).

51. Woody, G. E. et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA 300, 2003–2011 (2008).

52. Kakko, J., Svanborg, K. D., Kreek, M. J. & Heilig, M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 361, 662–668 (2003).

53. Fischer, G. et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction (Abingdon, England) 94, 1337–1347 (1999).

54. Krook, A. L. et al. A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. Addiction
55. Ling, W. et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 93, 475–486 (1998).

56. Lintzeris, N. et al. Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial. Am J Addict 13 Suppl 1, S29-41 (2004).

57. Mattick, R. P. et al. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 98, 441–452 (2003).

58. Neri, S. et al. Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology 179, 700–704 (2005).

59. Shufman, E. N. et al. The efficacy of naltrexone in preventing reabuse of heroin after detoxification. Biological psychiatry 35, 935–945 (1994).

60. Pani, P. P., Maremmani, I., Pirastu, R., Tagliamonte, A. & Gessa, G. L. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend 60, 39–50 (2000).

61. Schottenfeld, R. S., Pakes, J. R. & Kosten, T. R. Prognostic factors in Buprenorphine-versus methadone-maintained patients. J Nerv Ment Dis 186, 35–43 (1998).

62. Preston, K. L., Umbricht, A. & Epstein, D. H. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Arch Gen Psychiatry 57, 395–404 (2000).

63. Schottenfeld, R. S. et al. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatry 162, 340–349 (2005).
64. Fudala, P. J. et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. *N Engl J Med* **349**, 949-958 (2003).

65. Strain, E. C., Stitzer, M. L., Liebson, I. A. & Bigelow, G. E. Dose-response effects of methadone in the treatment of opioid dependence. *Annals of internal medicine* **119**, 23-27 (1993).

66. Hartnoll, R. L. et al. Evaluation of heroin maintenance in controlled trial. *Arch Gen Psychiatry* **37**, 877-884 (1980).

67. Strang, J. et al. Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. *Lancet* **375**, 1885-1895 (2010).

68. Zaks, A., Fink, M. & Freedman, A. M. Levomethadyl in maintenance treatment of opiate dependence. *JAMA: the journal of the American Medical Association* **220**, 811-813 (1972).

69. Strain, E. C., Bigelow, G. E., Liebson, I. A. & Stitzer, M. L. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. *JAMA* **281**, 1000-1005 (1999).

70. Petitjean, S. et al. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. *Drug Alcohol Depend* **62**, 97-104 (2001).

71. Guo, S. Efficacy of naltrexone Hydrochloride for preventing relapse among opiate dependent patients after detoxification. *Hong Kong J. Psychiatry* **11**, 2-8 (2001).

72. Krupitsky, E. M. et al. Naltrexone for heroin dependence treatment in St. Petersburg, Russia. *J Subst Abus. Treat* **26**, 285-294 (2004).

73. San, L., Pomarol, G., Peri, J. M., Olle, J. M. & Cami, J. Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. *Br J Addict* **86**, 20
983–990 (1991).

74. Krupitsky, E. M. et al. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. *J Subst Abus. Treat* **31**, 319–328 (2006).

75. Giacomuzzi, S. M., Ertl, M., Kemmler, G., Riemer, Y. & Vigl, A. Sublingual buprenorphine and methadone maintenance treatment: a three-year follow-up of quality of life assessment. *ScientificWorldJournal* **5**, 452–468 (2005).

76. Haasen, C. et al. Heroin-assisted treatment for opioid dependence: randomised controlled trial. *The British journal of psychiatry: the journal of mental science* **191**, 55–62 (2007).

77. Johnson, R. E., Jaffe, J. H. & Fudala, P. J. A controlled trial of buprenorphine treatment for opioid dependence. *JAMA: the journal of the American Medical Association* **267**, 2750–2755 (1992).

78. Krupitsky, E. et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. *Archives of General Psychiatry* **69**, 973–981 (2012).

79. Hartnoll, R. L. et al. Evaluation of heroin maintenance in controlled trial. *Arch. Gen. Psychiatry* **37**, 877–884 (1980).

80. Bruneau, J. et al. Management of opioid use disorders: a national clinical practice guideline. *Can. Med. Assoc. J.* **190**, E247–E257 (2018).

81. *Methadone Maintenance Treatment Program Standards and Clinical Guidelines*. (The College of Physicians and Surgeons of Ontario, 2011).

**Abbreviations**

**GENOA:** Genetics of opioid addiction, **OSATs:** opioid substitution and antagonist therapies, **PRISMA:** preferred reporting items for systematic reviews and meta-analyses, **HiREB:** Hamilton Integrated Research Ethics Board, **RCT:** randomized controlled trial, **OUD:** opioid use disorder

**Declarations**
Ethics approval and consent to participate

Participants were recruited as part of the Genetics of Opioid Addiction (GENOA) research collaborative between McMaster University and the Population Genomics Program. GENOA is a prospective cohort investigation approved by the Hamilton Integrated Research Ethics Board. Amendments to the GENOA study protocol to include new questions as part of our interview tool to allow for qualitative interviews exploring patient important outcomes was approved (HIREB #0168).

Consent for publication

This study does not include any individual persons data requiring consent for publication.

Availability of data and material

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests

Funding

This work was supported by the CIHR Drug Safety and Effectiveness Network (DSEN) grant (grant number: 126639) and CIHR (sponsor award number 156306). The funders had no role in study design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

Authors’ contributions

ZS, BD, and LT led the development of the project. BD, NS, MB, LN, CP, AW, JW, AB, NBM, AH, KC, BH, DR, PT, ZS and TB contributed to the development of the research protocol, which is published in the journal Systematic Reviews. BD, NS, MB, LN, CP, AW, JW, AB, NBM, AH, KC, BH, DR, PT, ZS and TB contributed to interpreting the data and writing the manuscript. ZS had full access to data from this investigation and she is accountable for the reliability of the data and the accuracy of all analyses performed.

Acknowledgements

We would like to sincerely thank everyone who contributed to the completion of this project. We
would like to specially thank Arnav Agarwal, and Joshua Kong for their initial help with the screening and data abstraction of studies. This project would not have been possible without the great collaboration cemented between GENOA and the CATC.

Tables

**Table 1: Summary of All Clinical and Social Outcomes Used to Establish Effectiveness for Trials in Opioid Addiction**

| Domains                              | Outcomes                          | Subdomains                                                                 |
|--------------------------------------|-----------------------------------|----------------------------------------------------------------------------|
| Abstinence and Substance Use Behaviour | *Illicit Opioid Use*              | Frequency of Illicit Opioid Use (Mean number opioid urine screens or percentage of positive screens, days of illicit use, assessed per treatment arm) |
|                                      |                                   | 'Dirty rate' measured using the number of urine screenings divided by the number of weeks of study participation |
|                                      |                                   | Time to relapse measured using the number of days between baseline and occurrence of the first opioid-positive urine screening |
|                                      |                                   | Failure to maintain abstinence                                            |
|                                      |                                   | Heroin use in preceding month at three, six, and twelve month interviews |
|                                      |                                   | Response to treatment measured as a reduction in heroin use, which was defined as 50% or more of negative specimens on urinalysis during week |
|                                      |                                   | Percentage of patients in a drug-free period, time elapsed between the first day of Naltrexone administration and the first evidence of opioid-positive urine test for opiate use (alternatively, the day on which the patient reported opiate abuse) |
|                                      |                                   | Abstinence from street heroin (zero use) in the past 30 days |
|                                      |                                   | Assessment of near (<2 opioid-positive urine screens) or full abstinence (0 opioid-positive urine screens) |
|                                      |                                   | Percentage of participants per treatment arm who maintained 12 consecutive opioid-free urine screens |
|                                      |                                   | Slip defined as occasional heroin use, less than three consecutive positive urine screens, and no withdrawal |
|                                      |                                   | Days to heroin relapse (3 consecutive opioid-positive urine screens) |
|                                      |                                   | Number of days a patient could remain abstinent by the longest duration of opiate-negative urine screens |
|                                      |                                   | Drug use history and routes of substance use at the global severity of all aspects of their current drug problem |
|                                      |                                   | Opioid relapse defined as everyday heroin use, consecutive positive urine tests, or report of opiate withdrawal |
|                                      |                                   | Degree of opioid substance abuse |

**Non-opioid Substance Use**

Frequency of poly-substance use (eg. Perce
| Health Risk Behaviour Related to Substance Use                                      | Injecting drug-use behaviour                                                                 |
|----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
|                                                                                 | Reduction in HIV risk behaviours                                                               |
| Money Spent or Gained on Illicit Opioid Consumption                               | Amount of money spent on illicit opioid consumption per month                                 |
|                                                                                 | Amount of money gained from illicit opioid consumption per month                             |
| Physical Health                                                                  | Drug Cravings                                                                                 |
|                                                                                 | Craving for Opioid Substances                                                                  |
| **Overdose**                                                                     | Overdose of illicit or prescribed opioid and other substances requiring medical attention     |
| Withdrawal Symptoms                                                              | Opioid physical withdrawal symptoms                                                             |
| **General Physical Health**                                                      | General physical health and well-being, an assessment of current physical symptoms, physical role limitations, bodily pain, physical comorbidity as well as medical history |
|                                                                                 | Physicians perception of disease severity or improvement compared to baseline                  |
|                                                                                 | Immune system functioning                                                                       |
|                                                                                 | Cardiac Function assessed with corrected QT measurements                                        |
|                                                                                 | Evaluation of patients meetings the categorical QTc prolongation thresholds across treatment groups (greater than 470 milliseconds for males and more than 490 milliseconds for females) |
| Psychiatric Health and Symptoms                                                  | Psychiatric symptoms                                                                           |
|                                                                                 | Psychiatric Assessment for Depression, Anxiety, and other psychiatric symptoms                  |
| **Psychological Adjustment** | Psychological and social adjustment |
|-----------------------------|-----------------------------------|
| **Global Quality of Life and Addiction Severity Assessments** (outcomes of combined domains) | **Composite Addiction Severity Scores** | Composite scores from addiction severity assessments encompass patients' physical, psychological, and social functioning, as well as their substance use behaviors. |
| **Global Quality of Life** | Quality of life assessment encompasses the physical, social, physical, and psychological well-being. |
| **Personal and Social Functioning** | **Criminal Behaviour** | Involvement in illegal activity |
| **Employment and Social Involvement** | Social stability assessed using current employment, volunteer, or social activities |
| **Relationships** | Evaluation of relationships and personal conflicts |
| **Personal Stability** | Evaluation of personal stability through assessment of housing and food consumption |
|------------------------|-----------------------------------------------------------------------------------|
| **Resource Utilization** | Service utilization Evaluation of how patients utilize available social services |
| **Intervention Adherence** | Retention in Treatment Number of patients remaining on the allocated intervention at the end of follow-up |
|                        | Number of patients remaining on the allocated intervention and maintained a standard of opioid-free urine set by the study coordinators at the end of follow-up |
|                        | Time until patient withdraws from treatment |
| **Intervention Compliance** | Days patients attended clinic as an assessment of how well the patient adheres to the treatment regime |
|                        | Assessment of medication adherence (evaluation of whether patient takes the medication prescribed) |
| **Successful Medication Induction** | At least one dose of medication by the 6th day of the study |
| **Intervention Acceptance** | Intervention Preference Assessment of final drug of choice (at end of cross-over trial participants could choose which therapy to remain on) |
|                        | Medication preferences (includes a proxy assessment of dosing adequacy) |
Table 2. Verbatim Answers to Qualitative Interview to Understand Goals of Therapy

| Participant | Verbal Answer                                                                 |
|-------------|-------------------------------------------------------------------------------|
| 1           | Remain abstinent from drugs                                                   |
| 2           | I don’t want to use drugs                                                     |
| 3           | Not use street drugs                                                          |
| 4           | Get off opioids completely                                                    |
| 5           | Maintain my job                                                               |
| 6           | Just get my life back; I’m still an addict and I don’t want it to sneak back on me |
| 7           | To not be sick anymore                                                        |
| 8           | Being completely off drugs, To never touch drugs again                         |
| 9           | Being able to control my addiction. Just living a life to take medication everyday |
| 10          | Not to use drugs                                                              |
| 11          | Being independent from methadone and drugs                                    |
| 12          | Pain control                                                                  |
| 13          | To get off methadone and never look back at any opioids                        |
| 14          | Managing my addictive personality, whether it is a drug addiction or not       |
| 15          | Get clean; not going back on opioid and not go back                            |
| 16          | Become drug free                                                              |
| 17          | Get off methadone; Be done with this all                                     |
| 18          | Get off it (methadone) completely                                             |

Table 3: Patient’s Response to Predetermined Treatment Goals

| Participant | Outcome #1                        | Outcome #2                          | Outcome #3                        |
|-------------|-----------------------------------|-------------------------------------|-----------------------------------|
| 1           | Money spent on drugs              | Overdose                            | Injecting                         |
| 2           | Stable relationships              | Coping                              | N/A                               |
| 3           | Employment                        | Housing                             | Depression                        |
| 4           | Stable relationships              | Money spent on drugs                | Sexual function                   |
| 5           | Employment                        | Stable relationships                | Housing                           |
| 6           | Abstinence from opioid use        | Employment                          | N/A                               |
| 7           | Regaining physical health         | Abstinence from opioid use          | N/A                               |
| 8           | Abstinence from opioid use        | Regaining physical health           | Coping                            |
| 9           | Missing Data                      |                                     |                                   |
| 10          | Abstinence from opioid use        | Depression                          | Coping                            | N/A                               |
| 11          | Abstinence from opioid use        | Drug craving                        | Money spent on drugs              | Regaining physical health          |
| 12          | Pain                              | Employment                          | N/A                               |                                   |
| 13          | Abstinence from opioid use        | Money spent on drugs                | Drug Craving                       | Stable relationships               |
| 14          | Drug craving                      | Stable relationship                 | Money spent on drugs              | N/A                               |
| 15          | Drug craving                      | Pain                                | Stable relationships              | Drug craving                       |
| 16          | Abstinence from opioid use        | Pain                                | Stable relationships              |                                   |
| 17          | Abstinence from opioid use        | Money spent on drugs                | Depression                        | Anxiety                           |
| 18          | Abstinence from opioid use        | Drug craving                        | Stable relationships              | N/A                               |

Figures
Figure 1

The preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram.
**Patient's First Outcome Choice**

| Outcome                                | Percentage |
|----------------------------------------|------------|
| Drug Craving                           | 11.76%     |
| Pain                                   | 5.88%      |
| Regaining Physical Health              | 5.88%      |
| Abstinence from Opioid Use              | 47.06%     |
| Employment                             | 11.76%     |
| Stable Relationships                    | 11.76%     |
| Money Spent on Drugs                   | 5.88%      |

*Caption:* Patients ranking of treatment goals from a “pre-determined” list provided during the qualitative interview. Patients were asked to rank which aspect of recovery meant the most to their addiction treatment. Patients were allowed to rank up to four items. The figure above illustrates the first ranked items.

**Figure 2**

First Ranked Treatment Goals Among Patient’s Receiving OSAT.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- PRISMA_2009_checklist.doc
- Final COREQ-checklist.pdf
- Supplementary Web Appendix.pdf